Home > Pulmonology > ERS 2019 > Infectious Respiratory Disease: the Role of Vaccines > Pneumococcal Vaccines: An Effective Way to Reduce COPD Hospitalisations

Pneumococcal Vaccines: An Effective Way to Reduce COPD Hospitalisations

Presented By
Prof. Antoni Torres, University Hospital Clinic Barcelona, Catalonia, Spain
Conference
ERS 2019
Trial
CAPiTA

Although there is increasing evidence of the protection offered by vaccination for pneumococcal disease, the majority of patients at risk in Europe are not vaccinated.

“Pneumonia is still a major health problem and a significant cause of mortality and morbidity worldwide,” said Prof. Antoni Torres (University Hospital Clinic Barcelona, Catalonia, Spain) [1]. Streptococcus pneumoniae was the main cause of morbidity and mortality in the Global Burden of Disease Study [2]. It contributed to more deaths than all other aetiologies combined in 2016 (1,189,937 deaths) [2].

Currently, two approved types of pneumococcal vaccines are available for adults: the pneumococcal polysaccharide vaccine (PPV)23 that contains a polysaccharide antigen and conjugate vaccines that contain polysaccharide antigens covariantly linked to a carrier protein. Pneumococcal conjugate vaccine (PCV)13, 10, and 7 belong to this group. The conjugate vaccines provide improved ...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on